Prosecution Insights
Last updated: July 17, 2026
Application No. 17/924,780

NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS

Final Rejection §102
Filed
Nov 11, 2022
Priority
May 18, 2020 — provisional 63/026,263 +1 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Merck Sharp & Dohme LLC
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
837 granted / 1032 resolved
+21.1% vs TC avg
Moderate +9% lift
Without
With
+9.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
67 currently pending
Career history
1087
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
21.7%
-18.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
33.4%
-6.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendment filed 2026 February 3 is considered. A search of claim 1 is extended to a compound of the following scope: NR3R4 forms a piperidine ring; X, Y, and Z are each CH; R2 is H; W is CH or N; and R1 is a substituted C3-alkyl group. In the previous action, the search was extended to a compound in which R3 is a heterocyclic group. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63/026263, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Variable R2 is different in the provisional application and does not provide support for examined variable R2. As shown by the teachings below, variable R2 is different scopes in the examined application and the provisional application. Consequently the effective filing date of the examined application is 2021 May 13. 17 / 924780 PNG media_image1.png 258 566 media_image1.png Greyscale PNG media_image2.png 152 568 media_image2.png Greyscale 63 / 026263 PNG media_image3.png 330 592 media_image3.png Greyscale PNG media_image4.png 222 576 media_image4.png Greyscale PNG media_image5.png 312 580 media_image5.png Greyscale Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 5-7, and 14 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by ZHOU (US 20150057248, published 2015 February 26). Zhou describes compounds HJC 1-24, HJC 1-81, and compounds A1-A5, and A8 (figure 1; figure 5A). In these compounds, the following definitions apply: NR3R4 forms a piperidine ring; X, Y, and Z are each CH; R2 is H; W is CH or N; and R1 is a substituted C3-alkyl group. Since R11 of examined claim 1 does not limit the substitution pattern of an alkyl group, this is prior art. PNG media_image6.png 122 286 media_image6.png Greyscale PNG media_image7.png 120 288 media_image7.png Greyscale PNG media_image8.png 412 340 media_image8.png Greyscale Conclusion Claims 1, 5-7, and 14 are not allowed. Claims 2-4, 8-13, 15-18, 22, 25, 29, 30, 37, 38, and 44-46 are objected to as being dependent upon a rejected base claim in relation to the scopes of the searches done, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Nov 11, 2022
Application Filed
Nov 04, 2025
Non-Final Rejection mailed — §102
Feb 03, 2026
Response Filed
May 22, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679841
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
4y 7m to grant Granted Jul 14, 2026
Patent 12679858
METAL IRIDIUM COMPLEX AND USE THEREOF
3y 7m to grant Granted Jul 14, 2026
Patent 12679818
RADIOACTIVE HALOGEN LABELING PRECURSOR COMPOUND
3y 2m to grant Granted Jul 14, 2026
Patent 12679825
CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR
3y 2m to grant Granted Jul 14, 2026
Patent 12668593
PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.3%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month